Targeting efficacy and anticancer activity of polymeric nanoparticles of SN-38 on colon cancer cell lines

被引:3
|
作者
Prasad, Shilpi [1 ]
Dangi, J. S. [2 ]
机构
[1] Siddhi Vinayaka Inst Technol & Sci, Dept Pharmaceut, Bilaspur 495001, Chhattisgarh, India
[2] SLT Inst Pharmaceut Sci, Dept Pharmaceut, GGV, Bilaspur, CG, India
关键词
Polymeric nanoparticles; Colorectal cancer; Cell line; Gamma Scintigraphy; Colon targeting; Camptothecin; LIPOSOME-BASED FORMULATION; IN-VITRO; METABOLITE SN-38; DELIVERY-SYSTEM; IRINOTECAN; BIODISTRIBUTION; CPT-11; STABILITY; ASSAY; VIVO;
D O I
10.1186/s43094-023-00462-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BackgroundColorectal cancer is the third most prevailing cancer in the whole world. Chemotherapeutic agents which are used for treatment have severe side effects and also have unwanted exposure to healthy cells. In the present study, polymeric nanoparticles of SN-38 were prepared (using cationic and anionic polymers). They were optimized by Box Behnken design and characterized for its physicochemical properties and in vitro drug release. Optimized formulation (CsENP) was evaluated for its targeting efficacy by Gamma Scintigraphy studies on Swiss Albino mice and in vitro Cytotoxic assay against colon cancer cell line, viz. HT-29.ResultsThe images of Whole body gamma scintigraphy imaging of Swiss Albino mice show that CsENP remained intact till 2 h and after that at 4 h imaging it started dispersing and releasing drug which continued till 20 h. In Organ distribution studies, no radioactivity was traced in heart from the formulation. Even in liver, spleen, kidney and lung trace radioactivity was seen after 6 h. In case of CsENP radioactivity was seen in small intestine after 2 h and maximum (87.8% radioactivity) is seen in colon and rectum area after 4 h. At equivalent concentrations, the in vitro cell viability of HT-29 cells after 72 h incubation time showed that CsENP have enhanced cytotoxicity.ConclusionsThe results obtained of Whole body gamma scintigraphy imaging and organ distribution of Swiss Albino mice show that CsENP is Colon targeting and was found to be effective against colon cancer cell lines.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Biotin decorated PLGA nanoparticles containing SN-38 designed for cancer therapy
    Mehdizadeh, Mozhdeh
    Rouhani, Hasti
    Sepehri, Nima
    Varshochian, Reyhaneh
    Ghahremani, Mohammad Hossein
    Amini, Mohsen
    Gharghabi, Mehdi
    Ostad, Seyed Nasser
    Atyabi, Fatemeh
    Baharian, Azin
    Dinarvand, Rassoul
    ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, 2017, 45 (03) : 495 - 504
  • [22] Preparation and in vitro evaluation of actively targetable nanoparticles for SN-38 delivery against HT-29 cell lines
    Ebrahimnejad, Pedram
    Dinarvand, Rassoul
    Sajadi, Abolghasem
    Jaafari, Mahmoud Reza
    Nomani, Ali Reza
    Azizi, Ebrahim
    Rad-Malekshahi, Mazda
    Atyabi, Fatemeh
    NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2010, 6 (03) : 478 - 485
  • [23] Interaction between SN-38 and 5-fluorouracil (5-FU) in renal cancer cell lines
    Sayer, V
    Darvill, N
    Joel, S
    Oliver, T
    Shamash, J
    BRITISH JOURNAL OF CANCER, 2002, 86 : S103 - S104
  • [24] Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations
    Niels Frank Jensen
    Keli Agama
    Amit Roy
    David Hersi Smith
    Thomas D. Pfister
    Maria Unni Rømer
    Hong-Liang Zhang
    James H. Doroshow
    Birgitta R. Knudsen
    Jan Stenvang
    Nils Brünner
    Yves Pommier
    Journal of Experimental & Clinical Cancer Research, 35
  • [26] Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations
    Jensen, Niels Frank
    Agama, Keli
    Roy, Amit
    Smith, David Hersi
    Pfister, Thomas D.
    Romer, Maria Unni
    Zhang, Hong-Liang
    Doroshow, James H.
    Knudsen, Birgitta R.
    Stenvang, Jan
    Bruenner, Nils
    Pommier, Yves
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2016, 35
  • [27] Delivery and activity of SN-38 by sacituzumab govitecan in breast cancer brain metastases
    Brenner, Andrew J.
    Pandey, Renu
    Chiou, Jennifer
    Floyd, John
    Surapreneni, Prathiba
    Kaklamani, Virginia
    Lathrop, Kate
    Crownover, Richard
    Tiziani, Stefano
    CANCER RESEARCH, 2021, 81 (04)
  • [28] SN-38 loading capacity of hydrophobic polymer blend nanoparticles: formulation, optimization and efficacy evaluation
    Dimchevska, Simona
    Geskovski, Nikola
    Sevski, Gjorgji Petru
    Chacorovska, Marina
    Popeski-Dimovski, Riste
    Ugarkovic, Sonja
    Goracinova, Katerina
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2017, 43 (03) : 502 - 510
  • [29] Schedule-dependent cytotoxicity of SN-38 in p53 wild-type and mutant colon adenocarcinoma cell lines
    Te Poele R.H.
    Joel S.P.
    British Journal of Cancer, 1999, 81 (8) : 1285 - 1293
  • [30] Combined efficacy of trifluridine and SN-38 in a 5-FU-resistant human colorectal cancer cell line
    Matsuoka, Kazuaki
    Kobunai, Takashi
    Takechi, Teiji
    CANCER RESEARCH, 2016, 76